Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arca Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ABIO
Nasdaq
2834
http://arcabio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arca Biopharma Inc
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
- Nov 6th, 2019 9:10 pm
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth?
- Nov 3rd, 2019 1:47 pm
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
- Sep 12th, 2019 12:30 pm
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
- Sep 11th, 2019 12:30 pm
Could The ARCA biopharma, Inc. (NASDAQ:ABIO) Ownership Structure Tell Us Something Useful?
- Sep 4th, 2019 5:37 pm
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
- Aug 1st, 2019 8:30 pm
One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price
- Jun 4th, 2019 11:09 am
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
- May 13th, 2019 1:00 pm
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update
- May 8th, 2019 8:30 pm
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
- May 1st, 2019 12:30 pm
ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial
- Apr 23rd, 2019 12:30 pm
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
- Mar 18th, 2019 12:30 pm
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
- Mar 6th, 2019 1:00 pm
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
- Feb 27th, 2019 9:15 pm
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
- Feb 20th, 2019 12:30 pm
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
- Jan 16th, 2019 1:30 pm
ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling
- Dec 26th, 2018 4:47 pm
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
- Dec 20th, 2018 9:01 pm
Scroll